

### Changes to the AWP Calculation for Stelara and Associated Biosimilars

#### Purpose of this communication:

- The purpose of this communication is to inform you that for claims with dates of service on and after December 15, 2025, CareCentrix is updating the pricing calculation for Stelara and associated biosimilars.

#### What do I need to know?

- CareCentrix is updating the Average Wholesale Price (AWP) calculation for Stelara IV (J3358) and associated biosimilars to reflect Maximum Allowable Costs (MAC) as calculated by CareCentrix.

| Medication Name | HCPCS |
|-----------------|-------|
| Stelara IV      | J3358 |
| Stegeyma        | Q5099 |
| Yesintek        | Q5100 |
| Wezlana         | Q5137 |
| Pyzchiva        | Q9996 |
| Selarsdi        | Q9998 |
| Otulf           | Q9999 |
| Imuldosa IV     | Q5098 |

- Reimbursement for these drugs will be based on the HCPCS unit of measure and MAC which can be found on the [Medication Updates](#) on the HomeBridge® provider portal. Generic drugs are encouraged when clinically appropriate.
- Individual drug codes within each therapy type listed above are subject to change on a quarterly basis and such changes are reflected on the [provider portal](#).

#### What do I need to do?

- Refer to the [Medication Updates](#) to view the reimbursement rates for these impacted services.

Thank you in advance for your cooperation and continued partnership.